登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002898 证券简称：*ST赛隆（维权） 公告编号：2025-027 赛隆药业集团股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 特别风险提示 1.赛隆药业集团股份有限公司（以下简称"公司"或"本公司"）于2025年4月25日披露了《2024年年度报 告》，经审计的年度报告数据显示，公司2024年度利润总额、净利润、扣除非经常性损益后的净利润三 者均为负值，且扣除后的营业收入低于3亿元。根据《深圳证券交易所股票上市规则》第9.3.1条规定， 公司股票交易于2025年4月28日被深圳证券交易所实施退市风险警示。若公司2025年度出现《深圳证券 交易所股票上市规则》第9.3.12条所规定的关于终止公司股票上市交易的相关情形之一，公司股票将面 临被终止上市的风险。 2.公司控股股东、实际控制人蔡南桂先生、唐霖女士于2025年5月18日与海南雅亿共赢科技合伙企业 （有限合伙）（以下简称"海南雅亿"） 签署了《关于赛隆药业集团股份有限公司之股份转让协议》 （以下简称《 ...

Core Viewpoint - *ST Kaiyuan (SZ300338) is facing a delisting risk despite achieving a positive net asset value for 2024, as the company has submitted an application to the Shenzhen Stock Exchange to revoke the delisting risk warning, which is still under review and uncertain [1][2]. Financial Performance - As of the end of 2023, *ST Kaiyuan reported a negative net asset value, triggering the delisting risk warning as per the Shenzhen Stock Exchange rules [2]. - The audited financial report for 2024 shows that the net asset value attributable to shareholders of the listed company is 25.83 million yuan, indicating a recovery from negative net assets in 2023 [2]. - For 2024, *ST Kaiyuan achieved an operating revenue of 171 million yuan, a significant decline of 49.98% year-on-year, with a net loss of 141 million yuan, although this represents a 48.60% reduction in losses compared to the previous year [4][5]. Industry Context - The company operates in the vocational education and training sector, which is highly competitive and sensitive to policy changes [4]. - The vocational education training industry is characterized as a light-asset, high-margin sector with strong growth potential, but it faces increasing competition due to enhanced government investment and policy improvements [4]. Risk Factors - Despite the positive net asset recovery, *ST Kaiyuan has reported negative net profits for six consecutive years from 2019 to 2024, raising concerns about its financial stability [5]. - The company is currently facing a pre-restructuring application from creditors, which adds to the uncertainty regarding its operational future [5].

Core Viewpoint - The transfer of 14.16% of shares from the controlling shareholders of Sailong Pharmaceutical to Hainan Yayi will result in a change of control, with Hainan Yayi becoming the new controlling shareholder, although the company will have no actual controller [1][3]. Group 1: Share Transfer and Control Change - The controlling shareholders Cai Nanguai and Tang Lin plan to transfer their shares at a price of 8 yuan per share, totaling 199 million yuan [1]. - After the transfer, Hainan Yayi will hold 24.60% of the voting rights in Sailong Pharmaceutical, making it the controlling shareholder [3]. - Hainan Yayi was established on May 15, 2025, specifically for this transaction and currently has no actual business operations [3]. Group 2: Financial Performance and Risks - Sailong Pharmaceutical has been facing financial difficulties, with only one profitable year since 2020, and has reported losses in other years [4]. - Revenue figures from 2020 to 2024 were 121 million yuan, 247 million yuan, 264 million yuan, 311 million yuan, and 264 million yuan, while net profits were -67.22 million yuan, -23.34 million yuan, -37.31 million yuan, 9.534 million yuan, and -33.1456 million yuan respectively [4]. - The first quarter of 2025 showed a revenue of 54.09 million yuan, a year-on-year decrease of 22.2%, and a net loss of 1.04 million yuan, a decline of 163.9% year-on-year [4]. Group 3: Regulatory and Market Context - Sailong Pharmaceutical's stock was placed under delisting risk warning on April 28, 2025, due to negative profit figures and revenue below 300 million yuan [5]. - The company has outlined strategies to improve its financial situation, including expanding sales channels, increasing marketing efforts, and optimizing internal management [6].

Group 1 - The company Jilin Huamei Electronics Co., Ltd. has been placed under delisting risk warning and continues to face other risk warnings starting from May 6, 2025, due to an audit report issued by Beijing Guofu Jiaying Accounting Firm that expressed an inability to provide an opinion on the company's 2024 annual financial report [1][4] - The company is also facing continued risk warnings because non-operating fund occupation exceeds 5% of the latest audited net assets, amounting to over 10 million yuan, and has not been resolved within one month [1][2] - The company is actively urging its controlling shareholder to take effective measures to raise funds and repay the occupied funds, aiming to resolve the fund occupation issue [2] Group 2 - The company emphasizes the importance of complying with the requirements of the China Securities Regulatory Commission's Jilin Regulatory Bureau and is committed to rectifying the related issues [2] - The company is enhancing internal controls and will strengthen the training on relevant laws and regulations to improve financial accounting and internal control systems [2] - The company's production and operational situation remains stable, and it will take effective measures to mitigate the negative impacts of the current issues while ensuring the protection of the rights of investors [2]

Group 1: Company Overview and Business Segments - The company operates in four main business segments: power distribution equipment, electric vehicle charging stations, photovoltaic and wind power EPC, and biomedicine [2][3][11] - The acquisition of 51% of Rui'en Pharmaceutical is a strategic move to enhance the company's presence in the biomedicine sector [11][12] Group 2: Financial Performance and Goals - In Q1 2025, the company reported a revenue of 60.76 million CNY, a year-on-year increase of 94.47% due to the consolidation of Rui'en Pharmaceutical [11][12] - The company aims to improve its overall financial performance and mitigate delisting risks by enhancing operational management and cost control [3][4][12] Group 3: Risk Management and Compliance - The company is under delisting risk warning due to negative net profit and low revenue, with efforts being made to resolve these issues [4][6][12] - The company plans to apply for the removal of risk warnings once it meets the necessary criteria set by the Shenzhen Stock Exchange [4][6] Group 4: Strategic Initiatives and Future Plans - The company intends to expand its market presence both domestically and internationally, focusing on partnerships and order fulfillment [4][11] - Emphasis will be placed on technological advancements and maintaining customer relationships to enhance operational efficiency and brand reputation [4][11] Group 5: Shareholder Engagement and Market Confidence - The company reassures shareholders that there are no current plans for major asset disposals or reductions in shareholding by major stakeholders [13] - Continuous efforts are being made to improve shareholder value and market confidence through strategic management and operational improvements [13]

Mergers and Acquisitions - Guangyang Co., Ltd. is planning to acquire 100% equity of Ningbo Yinqiu Technology Co., Ltd. through a combination of issuing shares and cash payment, along with raising matching funds. The company's stock will be suspended from trading starting May 19, 2025, and the transaction plan is expected to be disclosed within 10 trading days [1] - Electric Power Investment Energy Co., Ltd. is also planning to acquire equity in Inner Mongolia Baiyinhua Coal Power Co., Ltd. through issuing shares and cash payment, with potential matching fund raising. The company's stock will resume trading on May 19, 2025 [2] Risk Matters - Rui Ling Co., Ltd. announced that a significant shareholder, Shenzhen Lihan Investment Consulting Co., Ltd., plans to reduce its stake by up to 13.4867 million shares, which is no more than 3% of the total share capital. Additionally, executives Cheng Jun and Pan Wen plan to reduce their stakes by up to 124,000 shares (0.028%) and 99,000 shares (0.022%), respectively [3] - Yuejian Intelligent Co., Ltd. reported that its controlling shareholders plan to reduce their combined stake by up to 2.99%, with specific reductions from individual shareholders including the chairman and general manager [4] - New Meixing Co., Ltd. announced that its controlling shareholder, He Deping, plans to reduce his stake by up to 8.892 million shares, which is also no more than 3% of the total share capital [5] Delisting Risk Warning - Zitian Technology Co., Ltd. has been under suspension since March 17 and has failed to complete required rectifications by the deadline of May 16. As a result, the company's stock will be subject to a delisting risk warning starting May 20 [6]

证券代码：002868 证券简称：*ST 绿康 公告编号：2025-055 绿康生化股份有限公司 本公司及董事会全体成员保证信息披露真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏 特别提示： 了《2024 年年度报告》，鉴于公司 2024 年经审计期末净资产为-24,536,065.37 元，触及《深圳证券交易所股票上市规则》第 9.3.1 条(二)的规定，自 2025 年 4 月 30 日起，深圳证券交易所对公司股票交易实施退市风险警示。 证券交易所股票上市规则》第 9.8.1 规定的第（七）项，自 2025 年 4 月 30 日 起，深圳证券交易所对公司股票交易实施其他风险警示。若公司 2025 年度出现 《深圳证券交易所股票上市规则》第 9.3.12 条规定的情形，公司股票将被终止 上市。 投资"）、股东杭州义睿投资合伙企业（有限合伙）（以下简称"义睿投资"）、 上饶市长鑫贰号企业管理中心（有限合伙）（以下简称"长鑫贰号"）、杭州皓 赢投资合伙企业（有限合伙）(以下简称"皓赢投资"）与福建纵腾网络有限公司 （以下简称"纵腾网络"）签署了《股份转让协议》，约定由康怡投资、义睿投 资、长鑫贰号、皓 ...

Group 1 - The company, Fujian Zitian Media Technology Co., Ltd., has been ordered by the Fujian Securities Regulatory Bureau to correct its financial accounting reports due to false records, with a deadline of 30 days from the receipt of the decision [1][2] - The company's stock has been suspended since March 17, 2025, due to failure to complete the required corrections within the specified timeframe, and it will face delisting risk warnings if corrections are not made within two months of the warning [1][2] - As of May 16, 2025, the company has not completed the necessary corrections and has not engaged a qualified accounting firm, which may lead to the termination of its stock listing if the required actions are not taken [2][3] Group 2 - The company is expected to resume trading on July 7, 2025, if it discloses the annual report within the two-month suspension period [2][3] - The board of directors has acknowledged the situation and is conducting a self-examination, but has not yet submitted a rectification report to the Fujian Securities Regulatory Bureau [2]

| | 2024 年 | 2023 年 | 本年比上年增减 | 2022 年 | | --- | --- | --- | --- | --- | | 营业收入(元) | 24,594,583.59 | 144,040,552.02 | -82.93% | 86,256,162.59 | | 归属于上市公司股东 的净利润(元) | -52.784.096.15 | -62.580.095.29 | 15.65% | -81,070,520.63 | | 的扣除非经常性损益 | -63.240.797.87 | -79,842,966.04 | 20.79% | -88.314.359.02 | | 的净利润(元) | | | | | | 经营活动产生的现金 流量净额(元) | -24.178.911.97 | -48.448.801.36 | 50.09% | 88.319.783.83 | | 归属于上市公司股东 | | | | | *ST和科于4月29日发布股票交易被实行退市风险警示暨停牌公告。公司股票自2025年4月30日起被实 施"退市风险警示"处理，股票简称由"和科达"变更为"*ST和科"，证券代码仍 ...

Summary of Key Points Core Viewpoint - *ST Suwu's stock price has significantly declined, with a drop of 14.76% this week, reaching a near one-year low, indicating potential financial distress and market volatility [1][3]. Trading Information Summary - As of May 16, 2025, *ST Suwu's stock closed at 2.31 yuan, down from 2.71 yuan the previous week, marking a 14.76% decrease - The stock reached a weekly high of 2.84 yuan on May 12 and a low of 2.26 yuan on May 16 - The company's total market capitalization is currently 1.645 billion yuan, ranking 148th out of 151 in the chemical pharmaceutical sector and 5022nd out of 5147 in the A-share market [1]. Company Announcement Summary - Chairman Qian Qunshan is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of securities laws and regulations related to information disclosure - The controlling shareholder, Suzhou Wuzhong Investment Holding Co., Ltd., holds 122,795,762 shares, accounting for 17.24% of the total share capital, with 94.48% of these shares pledged - The company has received a qualified audit report from Zhongxing Caiguanghua Accounting Firm for the 2024 fiscal year, indicating issues with non-operating fund occupation by related parties - The stock has been placed under delisting risk warning (ST) and other risk warnings due to significant price fluctuations exceeding 12% over three consecutive trading days [1][3].